Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2018, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.
Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 6, 1, 5, 2, 5 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Haemophilus influenzae Type B Infections - Overview
Haemophilus influenzae Type B Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Haemophilus influenzae Type B Infections - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Cadila Healthcare Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Kaketsuken
LG Chem Ltd
Panacea Biotec Ltd
Sanofi Pasteur SA
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Wockhardt Ltd
Haemophilus influenzae Type B Infections - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + Haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis + poliomyelitis + Haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis + poliomyelitis + Haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-Hib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae Type B Infections - Dormant Projects
Haemophilus influenzae Type B Infections - Discontinued Products
Haemophilus influenzae Type B Infections - Product Development Milestones
Featured News & Press Releases
Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine- Hexaxim
Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Kaketsuken, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by LG Chem Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2018
Haemophilus influenzae Type B Infections - Pipeline by Wockhardt Ltd, H2 2018
Haemophilus influenzae Type B Infections - Dormant Projects, H2 2018
Haemophilus influenzae Type B Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018
Haemophilus influenzae Type B Infections - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
